Sep 24 |
Can-Fite gains after agreement for animal arthritis drug
|
Sep 24 |
Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary Osteoarthritis
|
Sep 16 |
Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health
|
Aug 30 |
Can-Fite BioPharma files to sell 1.77B shares of common stock for holders
|
Aug 30 |
Is Can-Fite BioPharma Ltd. (CANF) The Best Rated Penny Stock To Buy According to Analysts?
|
Aug 29 |
Can-Fite Biopharma GAAP EPS of $0.00, revenue of $0.32M
|
Aug 29 |
Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies
|
Aug 9 |
OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
|
Aug 8 |
Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds
|
Jul 29 |
Can-Fite Provides Namodenoson Patent Update
|